First American Trust FSB Sells 2,603 Shares of Novo Nordisk A/S $NVO

First American Trust FSB trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 12.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 18,800 shares of the company’s stock after selling 2,603 shares during the quarter. First American Trust FSB’s holdings in Novo Nordisk A/S were worth $1,298,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of NVO. Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S during the first quarter valued at approximately $30,000. NewSquare Capital LLC grew its holdings in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock worth $31,000 after purchasing an additional 282 shares during the last quarter. Disciplina Capital Management LLC increased its position in shares of Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 297 shares in the last quarter. Dagco Inc. purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the 2nd quarter worth $37,000. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on NVO. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Tuesday, November 11th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Wall Street Zen lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, UBS Group cut shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $59.20.

Novo Nordisk A/S Trading Up 0.5%

Shares of NYSE:NVO opened at $48.52 on Tuesday. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $112.52. The stock has a market cap of $216.63 billion, a price-to-earnings ratio of 13.33, a PEG ratio of 2.33 and a beta of 0.65. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average price of $54.44 and a 200-day moving average price of $60.85.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.